TSX runs higher on rate cut expectations
Chewy, Inc. (NYSE:CHWY), a leading online retailer of pet products with a market capitalization of $15.2 billion and an impressive 134% return over the past year, announced the appointment of Dr. Nat Goldhaber as a new independent director to its board, effective as of Thursday. Dr. Goldhaber brings a wealth of experience from various technology and venture capital firms to the board of the Florida-based company. According to InvestingPro, Chewy maintains strong financial health with a "GOOD" overall rating, though it currently trades at premium valuation multiples.
The board’s expansion from thirteen to fourteen members is part of Chewy’s ongoing governance and oversight strategy. Dr. Goldhaber’s term as a Class I director is set to expire at the company’s annual meeting of stockholders in 2026. His appointment is a strategic move, considering his background as Managing Director of Claremont Creek Ventures and founder of several successful companies, including CyberGold, Inc. InvestingPro analysis reveals that Chewy holds more cash than debt on its balance sheet and has maintained profitability with earnings per share of $0.91 in the last twelve months.
With past roles at high-profile ventures and public office, including President of Kaleida Labs and Vice President at Sun Microsystems, Dr. Goldhaber is expected to bring valuable insights to Chewy’s board. His expertise in clean energy and healthcare investments aligns with the company’s commitment to sustainability and innovation. Discover 12 more exclusive insights about Chewy’s performance and prospects with a subscription to InvestingPro, including detailed analysis of the company’s growth trajectory and market position.
Dr. Goldhaber’s compensation aligns with Chewy’s standard annual package for non-affiliated directors. Additionally, the company has entered into an indemnification agreement with him, similar to those with other board members. Chewy has confirmed that there are no undisclosed transactions requiring regulation S-K disclosure related to Dr. Goldhaber’s appointment.
The announcement, based on a press release statement, underscores Chewy’s efforts to strengthen its leadership team and enhance corporate governance. The addition of Dr. Goldhaber to the board is not the result of any arrangement with other persons, indicating Chewy’s independent decision-making in its board selection process.
In other recent news, Chewy Inc . has been the subject of several analyst reports highlighting the company’s financial performance and future prospects. TD Cowen adjusted its price target for Chewy shares to $44, down from $45, while maintaining a Buy rating. This adjustment followed Chewy’s fourth-quarter results, which exceeded expectations for both revenue and EBITDA, driven by an increase in Active Customers and strong operating leverage. RBC Capital Markets also reiterated its Outperform rating with a $42 price target, citing increased net customer additions and improvements in margin initiatives as key factors supporting their positive outlook.
Piper Sandler maintained its Overweight rating and $40 price target for Chewy, expressing confidence in the company’s growth prospects, especially in the pet care sector. Piper Sandler noted that veterinarians expect pet population growth into 2026, which could benefit Chewy. Additionally, Citizens JMP adjusted Chewy’s price target to $39 from $40 but upheld a Market Outperform rating, reflecting a cautious yet optimistic view of Chewy’s ability to navigate economic challenges.
Furthermore, Piper Sandler highlighted Chewy as a brand capable of managing the impacts of recent tariffs effectively, with minimal exposure to direct foreign sourcing. Chewy’s strategic initiatives, including its autoship program and expansion into veterinary services, have been recognized as strong pillars supporting its market performance. Overall, these recent developments indicate that analysts hold a generally positive outlook on Chewy’s financial health and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.